Under the banner of Greenery Group, Vela Diagnostics announced recently that, it is going to acquire the data analysis business of the cancer molecular diagnostic company lifecode, which located at Foster City, California, the USA, aims to using the series products of data integration network, data analysis and results report.

The chief executive of Vela Diagnostics pointed out that, this acquirement consolidated the leading position of Vela Diagnostics in the field of genomics analysis and reporting. The data analysis products and services will be connected with the new generation of gene sequencing reporting system of Sentosa®SQ, based on the latest technology to providing the related information about approved drugs, clinical tests and documents, somatic mutation, anti cancer drugs and targets.

The data analysis business of Lifecode Will be totally integrated into the subsidiary company of Vela Diagnostics,Vela Genomics, which focuses on the genomics services. Once the integration is accomplished, customers is able to sent their variation call file(VCF) and obtain the latest information about the approved drugs and clinical tests. Moreover, the software is able to trace the medical history and recognize the changes in those historical reports.

The announcement points that, it is not only representing the new entrance  into the market of genomics results analysis for Vela Diagnostics, also accomplished the present polymerase chain reaction (PCR) and the new generation of sequencing (NGS) process.